Get the Stockscreener App
19.29
1.79%
0.34
After Hours:
19.33
0.04
+0.21%
Bausch Lomb Corp stock is traded at $19.29, with a volume of 701.30K.
It is up +1.79% in the last 24 hours and up +17.41% over the past month.
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$18.95
Open:
$18.89
24h Volume:
701.30K
Relative Volume:
0.95
Market Cap:
$6.72B
Revenue:
$4.50B
Net Income/Loss:
$-456.00M
P/E Ratio:
-32.53
EPS:
-0.5929
Net Cash Flow:
$-137.00M
1W Performance:
-0.98%
1M Performance:
+17.41%
6M Performance:
+11.50%
1Y Performance:
+13.81%
1-Day Range:
$18.89
$19.46
1-Week Range:
$18.89
$19.56
52-Week Range:
$13.16
$21.00
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
Clearline Capital LP Acquires 411,404 Shares of Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Wall Street SWOT: Bausch + Lomb stock rides wave of eye health innovation - Investing.com
Bausch Health: A Buyout Bid Could Be The Ticket To Unlock Value - Barchart
Gabelli Funds LLC Purchases 78,000 Shares of Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Here's Why Bausch Health Stock Gained 14.7% In A Week - Barchart
Bausch + Lomb (NYSE:BLCO) Sees Strong Trading Volume After Analyst Upgrade - MarketBeat
Bausch + Lomb (NYSE:BLCO) PT Raised to $22.00 at HC Wainwright - MarketBeat
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? - Benzinga
Victory Capital Management Inc. Has $747,000 Stock Position in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Judge Tosses Class Action Against Bausch & Lomb - Law360
Jefferies maintains Buy rating on Bausch & Lomb stock - Investing.com
Bausch + Lomb Corporation stock gains on reports of private equity interest - Investing.com
Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors - GlobeNewswire Inc.
With Buyout Interest, Bausch + Lomb May Still Be Worth Interest At Current Levels - Seeking Alpha
Bausch & Lomb may be worth about $28 a share in takeoveranalyst (NYSE:BLCO) - Seeking Alpha
Bausch & Lomb Corp (BLCO) Shares Up 9.05% on Sep 18 - GuruFocus.com
Bausch & Lomb: Interested Buyers Prepare Bids as Potential Sale Work Underway - Morningstar
Bausch + Lomb, Calibre, Dexterra at 52-Week Highs - Baystreet.ca
Private equity suitors line up for Bausch + Lomb eyecare auction - Financial Times
Bausch Lomb Meets 80-Plus Relative Strength Rating Benchmark - Investor's Business Daily
Bausch Health Taps Jefferies to Refinance Debt, Aid Spinoff - Yahoo Finance
Op-ed: Here’s why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors - CNBC
Investing in Bausch + Lomb Corp (BLCO) Is Getting More Attractive - Knox Daily
Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It? - Investor's Business Daily
Bausch + Lomb’s stock soars 18% on report company is considering selling itself - MarketWatch
Bausch + Lomb (BLCO) Surges 14.5%: Is This an Indication of Further Gains? - Yahoo Finance
Bausch + Lomb’s stock soars 14% on report company is considering selling itself - MSN
Why Bausch + Lomb Rallied Today - Yahoo Finance
Bausch + Lomb Corp Inc. (BLCO) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle
Needham & Company LLC Reaffirms "Hold" Rating for Bausch + Lomb (NYSE:BLCO) - MarketBeat
Bausch & Lomb: Eyes Potential Sale and Excites Investors; Shares Surge - Morningstar
Contact Lens Supplier Bausch + Lomb Eyes Sale Amid Separation Challenges As Parent Bausch Health Faces Debt Issues - Yahoo Finance
Bausch + Lomb Stock Jumps Amid Reports Of A Sale - Yahoo Finance
Bausch Reportedly Eyes A Sale; Could J&J Or AbbVie Buy It? - Investor's Business Daily
Bausch + Lomb soars on report it’s exploring a sale - Yahoo Finance
Bausch + Lomb’s stock soars 14% on report company is considering selling itself - MarketWatch
Bausch + Lomb Soars on Report That It’s Exploring a Sale - Bloomberg
Bausch + Lomb (NYSE:BLCO) Hits New 12-Month High at $18.67 - MarketBeat
Bausch & Lomb shares jump on spin-off sale hopes - ShareCast
Bausch + Lomb considers sale: FT - Yahoo Finance
Bausch + Lomb explores sale amid parent company's debt woesreport - Baystreet.ca
S&P 500 Futures Flat in Premarket Trading; Nuvalent, Bausch + Lomb Lead - Barron's
Bausch + Lomb explores sale amid parent company's debt woesreport - Investing.com
Bausch + Lomb rises 13% on potential sale chatter (NYSE:BLCO) - Seeking Alpha
Stock Rotation Hits Megacaps as Apple Sinks 3%: Markets Wrap - BNN Bloomberg
bausch + lomb corporation Earnings dates - RTTNews
Bausch + Lomb eyeing sale amid spinoff concerns (NYSE:BLCO) - Seeking Alpha
Eyecare company Bausch + Lomb explores sale to end messy spin-off - Financial Times
Mazzo’s Trukera Medical Acquired by Bausch + Lomb - Orange County Business Journal
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors - GlobeNewswire Inc.
Orthokeratology Lens Market to Grow by USD 248 Million (2024-2028) as Global Myopia Rates Rise, Report Highlights AI's Role in Market TransformationTechnavio - The Malaysian Reserve
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):